Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,124 Mln
Revenue (TTM)
$249 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
21.6
Industry P/E
24.51
EV/EBITDA
200.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0
Face value
--
Shares outstanding
98,151,471
CFO
$-341.02 Mln
EBITDA
$-192.80 Mln
Net Profit
$-514.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
| 0.4 | 0.7 | 13.0 | 142.9 | 40.8 | 19.2 | 9.1 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
| 105.0 | -25.4 | 97.2 | -11.4 | 21.0 | -11.5 | 192.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
21.6 | 2,124.0 | 248.5 | -0.3 | 2.6 | -0.3 | -- | 21.6 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,120.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.2 | 2.8 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive... daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc. Address: 10 Earlsfort Terrace, Dublin, Ireland, D02 T380 Read more
CEO & Director
Mr. Gregory J. Divis Jr.
CEO & Director
Mr. Gregory J. Divis Jr.
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Avadel Pharmaceuticals PLC (AVDL) is $21.64 (NASDAQ) as of 13-Feb-2026 09:30 EDT. Avadel Pharmaceuticals PLC (AVDL) has given a return of 40.76% in the last 3 years.
Since, TTM earnings of Avadel Pharmaceuticals PLC (AVDL) is negative, P/E ratio is not available.
The P/B ratio of Avadel Pharmaceuticals PLC (AVDL) is 21.62 times as on 13-Feb-2026, a 282 premium to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-20.75
|
13.72
|
|
2023
|
-7.57
|
13.83
|
|
2022
|
-3.29
|
-21.41
|
|
2021
|
-6.13
|
6.05
|
|
2020
|
55.44
|
2.40
|
The 52-week high and low of Avadel Pharmaceuticals PLC (AVDL) are Rs 23.57 and Rs 6.38 as of 05-Apr-2026.
Avadel Pharmaceuticals PLC (AVDL) has a market capitalisation of $ 2,124 Mln as on 13-Feb-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Avadel Pharmaceuticals PLC (AVDL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.